Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZ14193391
- Development stage
- Preclinical
- Lead developer
- AstraZeneca
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
AZ14193391 is a radiolabeled small molecule PET imaging agent, specifically designed as a blood-brain barrier-permeable and subtype-selective poly(ADP-ribose) polymerase 1 (PARP1) radioligand. It is labeled with carbon-11 ([11C]) for use in positron emission tomography (PET) imaging. The compound enables non-invasive visualization and quantification of PARP1 expression in the brain and other tissues, supporting research into cancer and central nervous system disorders where PARP1 activity is relevant. AZ14193391 was developed to address the need for highly selective, brain-penetrant PARP1 PET tracers with improved imaging precision[6][7]. The agent has been used in clinical studies to assess pharmacokinetics, safety, tolerability, and its utility as an imaging biomarker[1][4].
- Other names
- carbon c 11 az14193391
02
Targets
PARP1 (Poly (adp-ribose) polymerase 1)
Beyond the preview
Go deeper on AZ14193391.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZ14193391.